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Erythroid Kruppel-like Factor (EKLF) is an erythroid-
specific transcription factor that plays a critical role in
g- to b-globin gene switching during development. To
identify essential domains required for EKLF transacti-
vation function, we cotransfected a human erythroleu-
kemia cell line (K562) with a locus control region g/Luc-
b/Cat reporter and an EKLF expression vector. In this
assay EKLF mediates a 500-fold induction of b/CAT ex-
pression compared with controls. To map essential
transactivation domains, progressive NH2-terminal and
internal deletion mutants of EKLF were constructed. All
EKLF mutants were expressed at wild-type levels, local-
ized to the nucleus, and bound DNA. When mutant EKLF
proteins were tested for b/CAT activation, a novel trans-
activation domain was identified. This novel domain,
encompassing amino acids (aa) 140–358, is sufficient for
maximal b/CAT activation. An 85-amino acid subdomain
within this region (aa 140–225) is essential for its activ-
ity. Interestingly, this central transactivation subdo-
main is functionally redundant with the amino-terminal
domain (aa 1–139). Thus, EKLF possesses at least two
potent transactivation domains that appear to function
in a redundant manner.
The genes encoding b-like subunits of human hemoglobin are
expressed in a tissue- and developmental stage-specific pattern
of expression (1). Expression is exclusive to erythroid tissues,
and e-, g-, and b-globin gene expression is predominately re-
stricted to the yolk sac, fetal liver, and bone marrow, respec-
tively. The genes are present within a 100-kb1 locus that con-
tains a potent 22-kb enhancer termed the locus control region
(LCR) (2–5). Several groups have proposed that precise tissue
and developmental regulation is accomplished by complex pro-
tein-protein interactions between factors that bind the LCR
and those that bind the promoters of individual genes (6, 7).
The competition model suggests that a number of erythroid-
specific and ubiquitous factors bind the LCR and enable this
region to function as a potent enhancer. Downstream genes
then compete for productive interactions with the LCR (2–5).
Presumably, yolk sac-, fetal liver-, and bone marrow-specific
factors bind to globin gene promoters and proximal enhancers
and provide individual genes with a competitive advantage for
interaction with the LCR at the appropriate developmental
stage.
Erythroid Kruppel-like Factor (EKLF) is one factor that is
critical for the developmental stage-specific switch from the g-
to b-globin expression (reviewed in Ref. 8). This erythroid-
specific transcription factor binds the b-globin promoter and
activates high level expression (9, 10). EKLF is a 358-amino
acid protein containing an amino-terminal, proline-rich trans-
activation region (aa 1–275) and a COOH-terminal DNA bind-
ing domain (aa 276–358) (10). The DNA binding domain con-
sists of three C2H2 Kruppel-like zinc fingers that bind
specifically to the CCACACCCT motif at 290 of the b-globin
promoter (11). Although EKLF also binds to the CACCC box in
the g promoter, the binding affinity to g CACCC is 8-fold lower
than the binding affinity for b CACCC and EKLF preferen-
tially activates the b gene in transient transfection assays (12).
Targeted deletion of EKLF in mice results in a drastic reduc-
tion in the b-globin gene expression, but g gene expression
remains unaffected (13, 14). Finally, persistence of g gene ex-
pression during development is observed in EKLF knockout
mice (15, 16). These observations are consistent with the view
that EKLF plays a central role in g- to b-globin gene switching
by binding specifically to the b promoter and providing a com-
petitive advantage for interactions with the LCR in adult
erythroid tissue. Recent studies also suggest that EKLF exerts
important functions at sites other than the b-globin promoter
(17, 18).
Although a large amount of information suggests a critical
role for EKLF in globin gene switching, the mechanisms un-
derlying EKLF transactivation functions are not clearly under-
stood. EKLF is expressed, and is functional at all developmen-
tal stages, yet its effects are apparent only during definitive
hematopoiesis (19–21). The molecular basis of this specificity is
unknown. The dissection of EKLF functional domains is an
important step in elucidating these mechanisms. Previous
studies have localized a transactivation domain at the amino-
terminal region (aa 1–104) (22). In this report, we describe the
identification of a new transactivation domain. This domain,
consisting of amino acids 140–358, is sufficient for maximal
transactivation of the b-globin promoter. Furthermore, an es-
sential region within this domain (aa 140–225) is completely
redundant with the amino-terminal transactivation domain
(aa 1–139).
EXPERIMENTAL PROCEDURES
Plasmid Constructions—The HA-EKLF plasmid was constructed by




encompassing the HA epitope at the NcoI site of the EKLF expression
plasmid pSG5/EKLF (10). This HA-EKLF plasmid was used as the
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parental plasmid for the generation of deletion mutants. Restriction
enzymes PvuII and Bpu10I cut in EKLF cDNA at positions correspond-
ing to codon 3. Restriction enzymes BsaI, NarI, and AvaI cut at posi-
tions corresponding to codons 139, 225, and 254, respectively. Restric-
tion enzyme SmaI cuts at positions corresponding to codons 155 and
255. Mutant HA-D4–139 was generated by ligating three fragments as
follows: a 0.7-kb AvrII-PvuII fragment, a 0.8-kb BsaI-BamHI fragment
(BsaI end was blunted by S1 nuclease), and a 3.3-kb BamHI-AvrII
fragment. Mutant HA-D4–225 was generated by digesting HA-EKLF
plasmid with Bpu10I and NarI. The Bpu10I end was blunted with
Klenow, and the NarI end was blunted with S1. The 4.6-kb
Bpu10I(blunt)-NarI(blunt) fragment was gel-purified and self-ligated.
Mutant HA-D4–254 was generated by digesting the HA-EKLF plasmid
with Bpu10I and AvaI. The Bpu10I end was blunted with Klenow, and
the AvaI end was blunted with S1. The 4.6-kb Bpu10I(blunt)-
AvaI(blunt) fragment was gel purified and self-ligated. Mutant HA-
D140–226 was generated by ligating two fragments: a 1.2-kb AvrII-BsaI
fragment (the BsaI end was blunted with Klenow), and a 3.7-kb NarI-
AvrII fragment (the Nar1 end was blunted with Klenow). Mutant HA-
D255–358 was generated by digesting the HA-EKLF plasmid with
SmaI and BamHI. The BamHI end was blunted with Klenow. The
4.6-kb SmaI-BamHI(blunt) fragment was gel-purified and ligated with
the 300-base pair SmaI fragment (codons 155–255) from EKLF cDNA.
All constructs were sequenced and purified twice on cesium chloride
gradients.
Cell Culture and Transfections—K562 cells were grown and electro-
porated as described previously (12). COS cells were grown in Dulbec-
co’s modified Eagle’s medium, 10% fetal bovine serum and transfected
with different mutants along with CMV-Lac-Z using the calcium chlo-
ride coprecipitation method. Forty-eight hours after transfection, nu-
clear extracts were prepared (23), and Western blots were performed
using ;50 mg of nuclear extracts that were normalized by b-gal activity.
The anti-HA antibody 12CA5-HRP (Roche Molecular Biochemicals) was
used at a 1:2500 dilution, and gels were developed using the ECL
system (Amersham Pharmacia Biotech). Transactivation assays were
performed as described previously (12). Each construct was tested in at
least three independent experiments. Within each experiment, each
construct was electroporated in duplicate. CAT assays were performed
in duplicate on each electroporated sample, and b-gal assays were
performed in triplicate on each electroporated sample. The CAT assay
values were normalized by b-gal values.
Indirect Immunofluorescence—Indirect immunofluorescence was
conducted as described previously (24), except that the cells were
blocked with 10% fetal bovine serum/phosphate-buffered saline for 10
min after the permeabilization step. Coverslips were mounted in media
containing propidium iodide (Vector Laboratories). 12CA5 anti-HA an-
tibody (generous gift of Dr. Susan Ruppert) was used (1:500 dilution) as
the primary antibody, and a FITC anti-mouse antibody (Santa Cruz)
was used as the secondary antibody (1:500 dilution). Images were
captured with a Hamamatsu 3CDC camera mounted on a Nikon eclipse
E800 microscope.
Gel Shift Assays—COS cell nuclear extracts that were normalized by
b-gal activity (;20 mg) as described above were used in gel shift assays
using a double-stranded oligomer encompassing the mammalian b pro-
moter CACCC box (8). The binding reactions were carried out in a
buffer containing 5 mM Tris, 0.5 mM dithiothreitol, 0.5 mM EDTA, 25
mM NaCl, and 1% Ficoll. Before loading the sample on the gel, a 0.1
volume of 20% Ficoll was added to each reaction. For supershift/abla-
tion assays, HA antibody was included in the binding reaction.
RESULTS
We performed a mutational analysis of EKLF using a previ-
ously established transient transfection assay (12) to map es-
sential transactivation domains. The transactivation assay uti-
lizes the human erythroid cell line K562, which expresses little
endogenous EKLF (12), and an LCR g-b reporter (HS2-g/Luc-
b/Cat) that contains wild-type human g- and b-globin promot-
ers (Fig. 1). In this assay, full-length EKLF activates b/CAT
expression 500-fold compared with vector alone; therefore, the
system provides a sensitive, quantitative assay for transacti-
vation domains. We first tagged EKLF at the NH2 terminus
with the influenza HA epitope (HA-EKLF) to allow detection of
the protein in transfected cells. HA-EKLF transactivated the
b-globin promoter in the HS2-g/Luc-b/Cat reporter at the same
level (500-fold) as wild-type EKLF. Using this parental plas-
mid, we constructed three progressive amino-terminal trunca-
tions of HA-EKLF: HA-D4–139 that deletes amino acids 4
through 139, HA-D4–225 that deletes amino acids 4 through
225, and HA-D4–254 that deletes amino acids 4 through 254
(Fig. 2A). The same methionine start site was retained for all
mutants to avoid differences in the site of translation initiation.
As an added control, untagged versions of each mutant were
also produced and tested in the same assay; no differences
between HA-tagged and untagged proteins were observed (data
not shown).
Each deletion construct was cotransfected with the LCR g-b
reporter and Lac-Z control and tested for the ability to trans-
activate the b-globin promoter. The results are depicted in Fig.
2B. In these experiments full-length HA-EKLF (WT) activated
the b-globin promoter 500-fold relative to the vector alone and
is depicted as 100%. The activities of different mutants are
expressed as a percentage of WT. Surprisingly, HA-D4–139
activated the b promoter at wild-type levels (99 6 21%) even
though this deletion removed the transactivation domain pre-
viously identified by Chen and Bieker (amino acids 1–104) (22).
A further 85 amino acid deletion (HA-D4–225) drastically re-
duced b/CAT activation to 2.9 6 2%. Deletion to amino acid 255
(HA-D4–254) resulted in very low levels of b/CAT activation
(1.0 6 0.6%). These data demonstrate that amino acids 140–
358 encompass a potent transactivation domain that is suffi-
cient for maximal transactivation of the b-globin promoter.
Furthermore, the results suggest that an 85-amino acid sub-
domain (amino acids 140–225) is critical for the function of this
domain.
To ensure proper integrity of the mutants, we first assessed
EKLF protein levels after transfection into COS cells. Mutant
constructs were cotransfected with a Lac-Z plasmid to control
for transfection efficiency, and Western blots were conducted
on normalized nuclear extracts using an anti-HA antibody.
These results are illustrated in Fig. 3. All mutant EKLFs were
detected at near wild-type levels, suggesting that the proteins
were stable.
We next assessed the subcellular localization of the mutants
to determine whether the inactivity of HA-D4–225 and HA-D4–
254 could be explained by protein mislocalization. Mutant con-
structs were transfected into COS cells, and HA-EKLFs were
detected by indirect immunofluorescence with a FITC-labeled
(green) anti-HA antibody (Fig. 4, A–E). Propidium iodide stain-
ing (red) was utilized to define the nucleus (Fig. 4, H–L), and a
two-color merge (Fig. 4, O–S) was used to assess EKLF nuclear
FIG. 1. Constructs used in the transactivation assay. The re-
porter plasmid HS2 g/Luc-b/Cat has been described previously (12).
This construct contains a human 1.5-kb KpnI-BglII HS2 fragment
linked to a human g-globin gene promoter (2299 to 137) driving the
firefly luciferase (Luc) gene and a human b-globin promoter (2265 to
148) driving the chloramphenicol acetyltransferase (Cat) gene. The
activator plasmid (pSG5/HA-EKLF) contains an SV40 promoter driving
HA-EKLF (wild-type or mutant). A CMV/Lac-Z gene was cotransfected
with the activator and the reporter into K562 cells to serve as a control
for transfection efficiency.
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localization. As illustrated in the figure, all mutant EKLFs
localized to the nucleus. These data suggest that the transcrip-
tional inactivity of HA-D4–225 and HA-D4–254 does not result
from protein mislocalization.
Finally, we examined all mutant EKLFs for the ability to
bind DNA. Gel shift assays were performed with nuclear ex-
tracts obtained from COS cells following transfection of the HA
constructs described above. The binding sequence was a la-
beled oligomer (20 base pairs) encompassing the mammalian
b-globin CACCC site (Fig. 5). Control extracts from cells trans-
fected with the vector alone are shown in lanes 2 and 3. The
background bands result from endogenous proteins that are
known to bind the CACCC motif (8); as expected, HA antibody
does not ablate or supershift these bands. Lanes 4 and 5 rep-
resent extracts from cells transfected with full-length HA-
EKLF. Unfortunately, the EKLF gel shift band is obscured by
a background band and, therefore, cannot be detected. How-
ever, unique gel shift bands that are distinct from endogenous
bands are detected for all deletion mutants. Lanes 6, 8, and 10
represent extracts from cells transfected with EKLF mutants
HA-D4–139, HA-D4–225, and HA-D4–254, respectively. Spe-
cific bands that migrate at the predicted size are observed in
each of these lanes. These data demonstrate that all mutant
EKLFs bind DNA. To confirm that unique bands are EKLF-
specific gel shifts, HA antibody was included in the binding
reactions. Lanes 7, 9, and 11 demonstrate that HA antibody
specifically ablates HA-D4–139, HA-D4–225, and HA-D4–254
FIG. 2. Deletion mapping of the transactivation domain. A,
schematic of HA-EKLF deletion constructs. The DNA-binding domain
(DBD) is shown as a solid box, and the HA tag is shown as a stripped
box. B, histogram of transactivation results. The HS2 g/Luc-b/Cat re-
porter was cotransfected with either vector alone, full-length, or dele-
tion mutants of HA-EKLF, and CMV-Lac-Z into K562 cells. CAT activ-
ities were normalized to b-galactosidase levels. Full-length HA-EKLF
activated b/CAT levels 500-fold relative to the vector alone and is
depicted as 100%. The transactivation capacities of the mutants are
shown as percentage of wild-type HA-EKLF activity. The error bars
denote S.E. of at least three independent experiments. The values for
each construct are as follows: vector, 0.2 6 0.07%; HA-D4–139, 99 6
21%; HA-D4–225, 2.9 6 2%; HA-D4–254, 1 6 0.6%; HA-D140–226, 95 6
23%.
FIG. 3. Protein expression levels. COS cells were cotransfected
with the indicated HA-EKLF mutant construct together with CMV-
Lac-Z and protein extracts (;50 mg) analyzed by immunoblotting with
12CA5 antibody to verify similar expression levels of each mutant
HA-EKLF protein. The protein extracts were normalized by b-gal ac-
tivity to control for transfection efficiency. The protein markers are
shown on the left.
FIG. 4. Nuclear localization of wild-type and mutant HA-EK-
LFs. COS cells were grown on coverslips and transfected with the
indicated HA-EKLF mutant constructs. After 48 h, indirect immuno-
fluorescence was performed using 12CA5 anti-HA primary antibody
and FITC anti-mouse secondary antibody. Mounting medium contained
propidium iodide, and cells were viewed through a fluorescence micro-
scope using different color filters. The FITC filter depicts the nuclei
expressing the HA tagged protein in green (panels A–G), Texas red filter
shows propidium iodide stained nuclei in red (panels H–N), and two-
color merge demonstrates colocalization (yellow, panels O–U). Repre-
sentative nuclei for each construct are shown. Over 100 transfected
cells for each construct were analyzed, and greater than 99% of these
cells showed similar results.
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gel shifts. We conclude that all EKLF mutants bind DNA and,
therefore, that the transcriptional inactivity of HA-D4–225 and
HA-D4–254 results from deletion of a novel transactivation
domain.
The results described above demonstrate that amino acids 4
to 139 of EKLF are dispensable for maximal activation of the
b-globin promoter, although this region encompasses the min-
imal activation domain described by Chen and Bieker (22). One
possible explanation for this apparent discrepancy is that dif-
ferent systems were utilized to define transactivation domains.
Chen and Bieker (22) used a GAL4 DNA binding domain fused
to EKLF and tested the ability of fusion proteins to activate a
heterologous target promoter (GAL4 binding sites-TATA-CAT)
in 32DEpo1 cells. On the other hand, we utilized native EKLF
and the natural b-globin promoter in K562 cells. To determine
whether the amino-terminal domain of EKLF would transacti-
vate in our assay, we constructed a new mutant, HA-D140–226
(Fig. 2A), that essentially fuses the amino-terminal domain
(amino acids 1–139) to the transcriptionally inactive mutant
HA-D4–225. We then tested the ability of this protein to trans-
activate the b-globin promoter in our HS2-g/Luc-b/Cat reporter
(Fig. 2B). Interestingly, this mutant activated the b promoter
at WT levels (95 6 23%). This result confirms that the amino-
terminal region of EKLF contains a potent transactivation
domain as originally described by Chen and Bieker (22). Fur-
thermore, our data demonstrate that this amino-terminal do-
main is functionally redundant with the domain at aa 140–225.
As expected, the HA-D140–226 EKLF protein is stable (Fig. 3),
localizes to the nucleus (Fig. 4 panels F, M, and T), and binds
DNA (Fig. 5, lanes 12 and 13).
DISCUSSION
The results described above identify a novel transactivation
domain in the erythroid-specific transcription factor EKLF.
This domain, which is contained within amino acids 140–358 of
the protein, is sufficient for maximal transactivation of the
b-globin promoter (see HA-D4–139, Fig. 2B). Furthermore, an
85-amino acid subdomain of this region (aa 140–225) is essen-
tial for activity; deletion of this subdomain dramatically re-
duces transactivation (HA-D4–225, Fig. 2B). Interestingly, this
subdomain can be functionally replaced by amino acids 1–139
(HA-D140–226, Fig. 2B), which contains a potent transactiva-
tion domain described by Chen and Bieker (22). These studies
demonstrate that EKLF possesses at least two transactivation
domains that function in a redundant manner. In this respect,
EKLF is similar to another Kruppel-like family member, Sp1,
which also contains two potent transactivation domains that
are functionally redundant (25). Mutant constructs designed to
delimit subregions within the 85-amino acid central domain (aa
140–225) produced unstable proteins (data not shown), pre-
cluding further definition of this domain.
Our results also demonstrate that amino acids 255–358 en-
compass sequences sufficient for nuclear localization; the HA-
D4–254 EKLF mutant efficiently localized to the nucleus
(Fig. 4, panels E, L, and S), although the protein did not
activate transcription. To confirm this result we generated a
new construct HA-D255–358 that deletes amino acids 255–358.
This mutant was expressed at WT levels in whole cell extracts
(data not shown). When tested for subcellular compartmental-
ization, the mutant localized exclusively to the cytoplasm (Fig.
4, panels G, N, and U). This result demonstrates that the first
254 aa of EKLF do not contain a nuclear localization sequence.
The best candidate for the nuclear localization sequence is
PKRSRR at position 260–265. This sequence is highly homol-
ogous to the nuclear localization sequence (PKRGRR) identi-
fied in other Kruppel-like family members (26).
The molecular basis for transactivation through the newly
identified, central domain of EKLF is not known. However,
some insight can be obtained from studies of the amino-termi-
nal domain. The activity of this domain is regulated by phos-
phorylation of a conserved threonine residue within the recog-
nition site of casein kinase-II (27). EKLF is heavily
phosphorylated on serine and threonine residues, and several
consensus sites for phosphorylation are present within the
central domain (27); therefore, the activity of this region may
also be regulated by phosphorylation. Alternatively, transacti-
vation may be a function of the proline-rich nature of this
region. The activation domains of several transcription factors
are rich in prolines (28), and previous studies have demon-
strated that a proline stretch of 10 residues is sufficient to
confer high transactivation capacity when fused to the GAL4
DNA binding domain (29). The entire EKLF protein is rich in
prolines, except for the zinc finger domain (aa 275–358); there-
fore, both the amino-terminal and central domains may func-
tion through proline-rich sequences.
The redundancy of amino-terminal and central domains
could be achieved in several ways. Both domains may interact
independently with the same coactivator. This has been ob-
served for the two redundant Sp1 activation domains, both of
which interact with the same coactivator, TAFII110 (a compo-
nent of the TFIID complex) (30). Alternatively, the two do-
mains may interact with different coactivators that have re-
FIG. 5. DNA binding activity of HA-EKLF proteins. Extracts
from transfected COS cells (described in the legend to Fig. 3) were used
in a gel shift assay using the b-globin CACCC site. Approximate 20-mg
extracts from either vector (lanes 2 and 3), HA-EKLF (lanes 4 and 5),
HA-D4–139 (lanes 6 and 7), HA-D4–225 (lanes 8 and 9), HA-D4–254
(lanes 10 and 11), or HA-D140–226 (lanes 12 and 13) were used in the
binding reactions and run on a 5% acrylamide gel. Arrows depict the
positions of bands corresponding to the mutants. The band correspond-
ing to WT (HA-EKLF) is predicted to comigrate with one of the two high
intensity background bands (the faster migrating band) and is therefore
obscured. One ml of the anti-HA antibody 12CA5 was used to ablate the
gel shift bands in the designated lanes (lanes 3, 5, 7, 9, 11, and 13). Lane
1 shows the probe run alone.
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dundant activities. Previous studies have demonstrated that
EKLF interacts physically with CBP, P300, and P/CAF in vivo,
and GATA-1 in vitro (31, 32). Furthermore, Armstrong et al.
(33) recently purified the SWI/SNF-related complex E-RC 1
based on its ability to interact functionally with EKLF in vitro.
Additional experiments will be required to define the coactiva-
tors that interact with each EKLF transactivation domain.
As mentioned above, EKLF is phosphorylated extensively,
and Zhang and Bieker (31) recently demonstrated that specific
lysines are acetylated (Lys261, Lys270). These post-translational
modifications may promote interactions with specific coactiva-
tors and factors of the basal transcription machinery. Differen-
tial post-translational modifications of the two transactivation
domains during development may provide a mechanism for the
temporal-specific transcriptional activity of EKLF on the b-glo-
bin promoter, and identification of additional EKLF interacting
proteins should provide insights into globin gene switching.
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